TARS - Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged 2026 revenue guidance ($670–$700M) disappointed, implying 18% annualized growth from the current quarterly run-rate. TARS is building a robust distribution moat, with nearly half of targeted ECPs prescribing Xdemvy weekly and direct-to-consumer activation up 40% QoQ.
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena's story reflects the experience of millions who live with symptoms for years before seeking care and receiving a proper diagnosis.
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.64 per share a year ago.
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026 , at 1:30 p.m. PT / 4:30 p.m.
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.
Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 34,442 shares of the company's stock, valued at approximately $2,820,000. Calamos Advisors LLC owned approximately 0.08% of Tarsus
Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis, with early signs of payoff seen, as sales now exceed SG&A expense. The company has appointed star biotech executive David Pyott, former CEO and Chairman of Allergan Inc, to the Board. TARS has H1'27 clinical catalysts from trials of lotilaner in Lyme-disease prevention/tick-killing and ocular rosacea.
Capricorn Fund Managers Ltd lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 90.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,982 shares of the company's stock after selling 218,038 shares during the period. Capricorn Fund Managers
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.
An executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, 2026. The transaction involved only direct ownership; no indirect entities or derivative securities were reported.
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) General Counsel Bryan Wahl sold 4,125 shares of the firm's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $283,428.75. Following the completion of the sale, the general counsel directly owned 68,190 shares
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) insider Dianne Whitfield sold 4,174 shares of the business's stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the transaction, the insider owned 35,028 shares of the company's
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) insider Dianne Whitfield sold 4,071 shares of the company's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $279,718.41. Following the completion of the transaction, the insider owned 39,202 shares in the company,
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS - Get Free Report) General Counsel Bryan Wahl sold 4,084 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total transaction of $283,511.28. Following the completion of the sale, the general counsel owned 72,315 shares of